Cyagen and Neurophth Enter AI-AAV Collaboration for Ophthalmic Gene Therapy

Discover How AI Accelerates Ophthalmic Gene Therapy - Register Now!Подробнее

Quick Q&A with AI Marvin | How to Choose CAR-T Target CellsПодробнее

Our Experience at 3rd Annual Gene Therapy for Ophthalmic DisordersПодробнее

Webinar Teaser | Gene Therapies for Rare Diseases: Advancing Research with Humanized Models and AIПодробнее

why choose AAV for eye disease? | Episode 1Подробнее

Quick Q&A with AI Marvin｜What is AAV and Gene TherapyПодробнее

why choose AAV for eye disease? | Episode 2Подробнее

Webinar - Exploring Validation Studies for AI-Based in silico Techniques in AAV Gene TherapyПодробнее

Preclinical Ophthalmology Research Solutions by CyagenПодробнее

FirstThought Focus: Adeno-Associated Virus (AAV) Vectors in Gene Therapies with Guangping Gao, PhDПодробнее

Automated parallel AAV characterization with new tools for gene therapyПодробнее

Cell and Gene Therapy workshop 2: Hands-on Curriculum, Analytics, and EquipmentПодробнее

2022 NDF GNEM Symposium with Katherine Koczwara: Developing An AAV Gene Therapy For GNEM: Part llПодробнее

Optimizing AAV vectors with AIПодробнее

Can We Streamline How AAV Gene Therapies Are Developed?Подробнее

REGENXBIO: AAV Gene Therapy Company With 4 Internal Clinical-Stage ProgramsПодробнее

AI in eye scans helps improve diagnosis of inherited retinal diseaseПодробнее

基因治疗华山论剑第二期｜AI+AAV研究进展及眼科平台介绍Подробнее

AI-Enabled Cell & Gene Therapy Manufacturing: What's Next?Подробнее